C-D2ABMitoconix Bio
mitochondrial fragmentation inhibition, neurodegeneration
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-D2AB
C-D2ABC-D2ABmitochondrial fragmentation inhibition, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Mitoconix Bio mitochondrial fragmentation inhibition, neurodegeneration
Mitoconix Bio is developing disease-modifying therapeutics for neurodegenerative diseases by targeting mitochondrial health. Its lead drug is described as a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction, with demonstrated in vivo efficacy in Huntington's and Parkinson's disease animal models and activity in patient-derived cells across HD, PD, and AD. The technology was developed by Prof. Daria Mochly-Rosen and her team at Stanford University and exclusively licensed from Stanford.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Mitoconix Bio — Early mechanism · Bottom quartile. Derived deterministically from 1 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic